Express Pharma - Express Pharma

Asks sponsor to provide details of payment to investigators

Triples the production capacity for hormonal products

Are indicated for short-term treatment for healing and symptom relief of active duodenal ulcer

To treat colorectal and breast cancers

To develop a novel class of antibiotics, a new strategic therapeutic area for Debiopharm

To market CytoSorb, a‘first-in-class’ therapy for Sepsis management

Application filed to US FDA for generic version of Absorica

Is indicated for relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses

To promote Locoid lotion to US pediatricians

10 therapies have outgrown the IPM growth